Spots Global Cancer Trial Database for Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Official Title: A Pilot Study to Assess Feasibility of Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation

Study ID: NCT03812289

Conditions

Hepatocellular Carcinoma

Interventions

Quality-of-Life Assessment

Questionnaire Administration

Stereotactic Body Radiation Therapy

Study Description

Brief Summary: This trial studies how well stereotactic body radiation therapy works in treating patients with liver cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.

Detailed Description: PRIMARY OBJECTIVE: I. Assess the use of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC) patients with advanced liver cirrhosis as a feasible approach to providing localized disease control that adequately suffices liver transplant eligibility criteria. SECONDARY OBJECTIVE: I. Assess preliminary efficacy and toxicity in HCC patients with advanced cirrhosis following liver SBRT. EXPLORATORY OBJECTIVE: I. Assess qualify of life in HCC patients with advanced cirrhosis following liver SBRT. OUTLINE: Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 6 weeks, then every 3 months for up to 2 years.